HC Wainwright & Co. Reiterates Buy on Iovance Biotherapeutics, Maintains $32 Price Target

Benzinga · 06/03 11:39
HC Wainwright & Co. analyst Joseph Pantginis reiterates Iovance Biotherapeutics (NASDAQ:IOVA) with a Buy and maintains $32 price target.